The Challenges for Biosimilars in the EU
This article was originally published in SRA
Executive Summary
The regulatory framework for biosimilar medicines in the European Union is working and delivering products. Once approved, however, the products are not penetrating the market as quickly as generics firms had hoped. This was one of the key messages to emerge from the 7th European Generic medicines Association Annual Symposium on Biosimilar Medicines in London on 23-24 April.